NEW YORK, NY–(Marketwired – December 01, 2016) – Crystal Research Associates, LLC announced today that it has issued an Executive Informational Overview® (EIO) on Hemispherx Biopharma, Inc. (NYSE MKT: HEB). The full 60-page report is available on Crystal Research Associates’ website at www.crystalra.com.
Hemispherx Biopharma, Inc. is a specialty pharmaceutical company addressing critical unmet medical needs. Hemispherx has invested over two decades of R&D into safe, effective ways to modulate and amplify the immune system, and is now poised to enter a confirmatory Phase III U.S. trial with an RNA macromolecule that could become the only FDA-approved therapy for chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME). This candidate, Ampligen®, was approved for CFS/ME in Argentina in August 2016 and is available to patients in Europe through an early access program (EAP). CFS/ME is a debilitating disease with no known treatment to date but very active patient advocacy groups.
Hemispherx also holds rights to an FDA-approved product for genital warts, Alferon N Injection®, which is believed to be the world’s only approved natural interferon (IFN). Hemispherx has refined Alferon’s manufacturing to drastically increase efficiencies and reduce costs, and now seeks FDA approval for the new production method before relaunching Alferon. Hemispherx is headquartered in Philadelphia with GMP manufacturing and research facilities in New Jersey.
Be the first to hear about Crystal Research’s new report releases and upcoming media coverage. Follow us at http://www.crystalra.com/blog for more coverage.
About Crystal Research Associates, LLC
For the past decade, Crystal Research Associates, LLC (www.crystalra.com) has successfully articulated the exceptional stories of small- and mid-cap companies to the Wall Street investor community. Our methods are well-established and diverse, from compiling and disseminating objective, factual information for both institutional and retail investor audiences to capitalizing on our expansive line of targeted distribution channels, which include industry-leading financial data and information providers. Our distribution efforts are accompanied by the use of prominent social media channels and by strategic and targeted appearances on national news programs and print media.
Crystal Research Associates is led by Wall Street veterans, Jeffrey Kraws and Karen Goldfarb. Together, Kraws and Goldfarb have built a unique business model, capitalizing on decades of experience as an award-winning sell-side analyst team to produce institutional-quality industry and market research in a manner that is easily understood by investors and consumers. Our firm’s approach has been proven successful over the years as our products are published and available on Bloomberg, Thomson Reuters/First Call, Capital IQ, FactSet, and scores of other popular forums.
Forward-Looking Safe Harbor Statement
Statements in this news release regarding future financial and operating results, potential applications of the Company’s technology, opportunities for the Company, and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,” and similar expressions) should also be considered forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including limited operating history, need for future capital, and economic conditions generally. Additional information on potential factors that could affect results and other risks and uncertainties are detailed from time to time in the Company’s periodic news and reports. Crystal Research Associates’ compensation is a cash amount of thirty-nine thousand, five hundred U.S. dollars for its services in creating this report and for updates.
These statements, and other forward-looking statements, are not guarantees of future performance and involve risks and uncertainties. Crystal Research Associates assumes no obligation to update any of the forward-looking statements in this release.
Contact:
Jeffrey J. Kraws/Karen B. Goldfarb
Crystal Research Associates, LLC
P: (609) 306-2274, F: (609) 395-9339
